Global Genetic Disorders Partnering 2023: Trends, Financials and Players from Every Deal Since 2016
ResearchAndMarkets.com has released the report "Global Genetic Disorders Partnering 2016-2023," providing a comprehensive overview of genetic disorder deals signed worldwide since 2016. The report captures key aspects including deal trends, financial terms, and the most active dealmakers in the biopharma industry. It includes detailed analyses of deal structures, contract documents, and financial metrics, such as headline values, upfront payments, and royalty rates. Covering multiple genetic disorders like Cystic Fibrosis and Huntington's Disease, this report aims to be an essential resource for stakeholders in genetic disorder collaborations.
- Comprehensive analysis of over 650 genetic disorder deals since 2016.
- Detailed financial metrics including headline values and royalty rates.
- Access to actual contract documents for a deeper understanding of agreements.
- Covers a variety of genetic disorders, enhancing the report's relevance.
- None.
Global Genetic Disorders Partnering 2016 to 2023 provides the full collection of genetic disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
- Trends in genetic disorders partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Genetic disorders partnering agreement structure
- Genetic disorders partnering contract documents
- Top genetic disorders deals by value
- Most active genetic disorders dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive genetic disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering genetic disorders deals.
The report presents financial deal terms values for genetic disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of genetic disorders dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in genetic disorders dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading genetic disorders deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active genetic disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the
Chapter 5 provides comprehensive access to genetic disorders deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the
Chapter 6 provides a comprehensive directory of all genetic disorders partnering deals by specific genetic disorders target announced since 2016. The chapter is organized by specific genetic disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all genetic disorders partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in genetic disorders partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genetic disorders technologies and products.
Report scope
Global Genetic Disorders Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genetic disorders trends and structure of deals entered into by leading companies worldwide.
Global Genetic Disorders Partnering 2016 to 2023 includes:
- Trends in genetic disorders dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of genetic disorders deal contract documents
- Comprehensive access to over 650 genetic disorders deal records
- The leading genetic disorders deals by value since 2016
- Most active genetic disorders dealmakers since 2016
The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.
In Global Genetic Disorders Partnering 2016 to 2023, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Genetic Disorders Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 650 genetic disorders deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Selection of Companies Mentioned
- 4D Molecular Therapeutics
- AAVLife
- Abbvie
Abby Grace Foundation - Abeona Therapeutics
- AdAlta
- Addex Therapeutics
- ADMA Biologics
- Aequus Pharmaceuticals
Affectis Pharmaceuticals Affymetrix Agena Bioscience Agilis Biotherapeutics - AGTC
AiLife Diagnostics Akcea Therapeutics Alana Healthcare - Alcyone Lifesciences
- Aldeyra Therapeutics
- Alexion Pharmaceuticals
- AllCells
- Allergan
- Alnylam Pharmaceuticals
- Altamira Pharma
Altius Institute for Biomedical Sciences - Ambry Genetics
American Heart/Stroke Association American Society of Human Genetics - AmerisourceBergen
- Amgros
- Amicus Therapeutics
AMO Pharma - AmorChem
- Angion Biomedica
- Annapurna Therapeutics
Antabio - Anthera Pharmaceuticals
ANZAC Reserach Institute AOP Orphan Pharmaceuticals - APG Bio
- Arbor Biotechnologies
- Arch Biopartners
- Arcturus Therapeutics
- Aridis Pharmaceuticals
Ariosa Diagnostics ArmaGen - ArQule
- Aruvant Sciences
Asklepion Pharmaceuticals - Astellas Pharma
- AstraZeneca
Attain Health Auburn University Audentes Therapeutics Bambino Gesu Children's Hospital - Bayer
Baylor College of Medicine - Baylor Genetics
- Berg
- Beyond
Batten Disease Foundation - BGI Americas
Bicycle Therapeutics - biOasis Technologies
- BioAxone Therapeutic
- BioBlast Pharma
- Biogen
- Biohealth Innovation
Bioiatriki - BioMarin Pharmaceutical
Biomedical Catalyst Fund (UK )- Biomnis
BioPontis Alliance - BioRealm
- BioSensics
Bioverativ BioXcel Bloom Burton - Bluebird Bio
- Blueprint Medicines
Boehringer Ingelheim Brammer Bio - BridgeBio Pharma
Brigham and Women's Hospital - Bristol-Myers Squibb
Buck Institute for Age Research California Institute for Biomedical Research California Institute for Regenerative Medicine Calimmune - Camurus
CANbridge Life Sciences Cancer Prevention Pharmaceuticals Capnia - CARB-X
- Cardinal Health
Case Western Reserve University - Casma Therapeutics
Castle Creek Pharmaceuticals - Celgene
Center for Human Genetics and Laboratory Medicine Centers for Disease Control and Prevention - Centogene
Centre for Drug Research and Development (CDRD)- CFTechnology.org
Charcot-Marie-Tooth Association CHDI Foundation - ChemDiv
- Children's Hospital Los Angeles
Children's Hospital of Philadelphia Children's National Health System Children's Hospital Oakland Research Institute (CHORI)- Chondrial Therapeutics
Cincinnati Children's Hospital Medical Center - Claire's
Place Foundation - Claritas Genomics
Clementia Pharmaceuticals Clinic for Special Children Clinigen Columbia University Medical Center - Concert Pharmaceuticals
Confluence Pharmaceuticals Congenica - Corbus Pharmaceuticals
Courtagen Life Sciences - CRISPR Therapeutics
- CTD Holdings
- Cure Duchenne
Cure Sanfilippo Foundation CURx Pharmaceuticals - Cyclacel Pharmaceuticals
- Cypher Genomics
Cystic Fibrosis Foundation - Cystic Fibrosis Foundation Therapeutics
Cystic Fibrosis Trust Cystinosis Research Foundation - Dainippon Sumitomo Pharma
Daktari Diagnostics - Dalton Pharma Services
- DarioHealth
- DaRui Biotech
- David and
Barbara Roux - DBV Technologies
- de
Duve Institute DefiniGEN Department of Health and Human Services Department of Veterans Affairs - Dermelix Biotherapeutics
- Dicerna Pharmaceuticals
- Dilaforette
- Dimension Therapeutics
DMS Health Technologies - Duchenne Therapy Network
Duke University Dynacure Dystrophic Epidermolysis Bullosa Research Association of America Edico Genome Edimer Pharmaceuticals - Eiger BioPharmaceuticals
- Elevian
- Elexopharm
- Eli Lilly
- Elixirgen
- Elucigene
- Emergent BioSolutions
Emmaus Life Sciences Emmaus Medical Emory University - EnBiotix
Enterprise Therapeutics - Enzyvant Science
- EpiDestiny
- Ergomed
- Erytech
EspeRare Foundation Essentialis - Esteve
- Eureka Genomics
- EUSA Pharma
- Evotec
- Ewopharma
- Exemplar Genetics
- Fabric Genomics
- Facio Therapies
Ferring Pharmaceuticals - Fertility SOURCE Companies
Fibrocell Science - Flemish agency for Innovation by Science and Technology
- Fluidigm
Fondazione Telethon Food and Drug Administration (FDA)- Fortress Biotech
- Foundation For Angelman Syndrome Therapeutics
Foundation for the Children of the Californias Fox Chase Cancer Center FRAXA Research Foundation Friedreichs Ataxia Research Alliance FSHD Global Research Foundation Fudan University Fujitsu Laboratories - Fulcrum Therapeutics
- Fulgent Genetics
- Galapagos
- Gamida Cell
Geisinger Health System Genable Technologies - Genea Biocells
GeneDX GenePeeks Genethon Genetic Alliance Geneva University Hospitals - Genoma
Genome Institute of Singapore - Genomic Vision
Genzyme George Washington University - Gilead Sciences
- GlaxoSmithKline
Global Blood Therapeutics GNS Healthcare Good Start Genetics Grace Wilsey Foundation Great Ormond Street Hospital (GOSH)- GtreeBNT
Harvard University - Helix
Heptares Therapeutics Hereditary Neuropathy Foundation - Hillhurst Biopharmaceuticals
- Horizon Discovery
Icagen Icahn School of Medicine at Mount Sinai - Illumina
- Immuneering
- ImmunoQure
Imperial College London - Imperial Innovations
- In-Depth Genomics
Indiana University - Indiana University-Purdue University Indianapolis
Indian Institute of Science Education and Research - InformedDNA
- Innovate
UK Inova Translational Medicine Institute Inserm Inserm Transfert Insight Centre for Data Analytics - Insilico
- Insmed Inc
Institute for Genome Statistics andBioinformatics Institute of Child Health Institute of Human Genetics - Intel
Intrexon - Intrinsic LifeSciences
- Invitae
- Ionis Pharmaceuticals
- ISIS Innovation
Israeli Ministry of Industry and Commerce IXICO Jackson Laboratory Janssen Pharmaceuticals - Jazz Pharmaceuticals
Jeffrey Modell Foundation - Juvenescence
K-PAX Pharmaceuticals Kadmon Pharmaceuticals - Kamada
- Kings College London
Komodo Health La Jolla Pharmaceutical - Lannett
Laurent Pharmaceuticals Lead Discovery Center - Leadiant Biosciences
- Leidos
- Lenus Therapeutics
Les Laboratoires Servier - Levo Therapeutics
LFB Biotechnologies - Ligand Pharmaceuticals
Linda Crnic Institute for Down Syndrome Louisiana State University Lumicera Health Services - Luminex
- Lundbeck
- Lysogene
- Mallinckrodt Pharmaceuticals
- ManRos Therapeutics
Marnier-Lapostolle Foundation Massachusetts Eye and Ear Infirmary Massachusetts General Hospital Massachusetts Institute of Technology - Matinas Biopharma
Mauli Ola Foundation - Maxcyte
Maxor National Pharmacy McGill University - McKesson
Medgenics Medical College of Wisconsin Medical University of South Carolina - Medison Pharma
MedPharm - MeiraGTx
- Merck and Co
- Merck KGaA
Mitsubishi Tanabe Pharma - Moderna Therapeutics
- Molecular Stethoscope
- Morphic Therapeutic
Mount Sinai Medical Center Murdoch Childrens Research Institute - Mustang Bio
Mylan Laboratories - Nanopharmacia
- NantHealth
- Napa Therapeutics
- Natera
National Center for Advancing Translational Sciences (NCATS)- National Heart
Lung and Blood Institute National Human Genome Research Institute National Institute of Allergy and Infectious Diseases National Institute of Child Health and Human Development National Institute of Mental Health National Institute of Neurological Disorders and Stroke - National
Institute on Aging National Institutes of Health National Newspaper Publishers Association National Organization for Rare Disorders National Psoriasis Foundation National Science Foundation National Taiwan University Hospital Nationwide Children's Hospital - Navitas
Necker Hospital - Neurocrine Biosciences
- NeuroCycle Therapeutics
- NeuroPointDX
- Neurotrope BioScience
- NeuroVive Pharmaceutical
New York Blood Center New Zealand Pharmaceuticals NextCODE Health - NextGxDx
NightstaRx - Nippon Chemiphar
- Nippon Shinyaku
- Novartis
- Novation
Novogen - Novo Nordisk
Novoteris - Numedicus
- Onconova Therapeutics
- Oraxion Therapeutics
Orchard Therapeutics ORIG3N - Origin Biosciences
Orsini Healthcare Specialty Pharmacy - Ovid Therapeutics
- Oxford BioMedica
For more information about this report visit https://www.researchandmarkets.com/r/prpsk6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For
For GMT Office Hours Call +353-1-416-8900
Fax (outside
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-genetic-disorders-partnering-2023-trends-financials-and-players-from-every-deal-since-2016-301789871.html
SOURCE
FAQ
What is the focus of the report "Global Genetic Disorders Partnering 2016-2023"?
Which genetic disorders are included in the report?
What financial metrics are analyzed in the report?
How many genetic disorder deals are documented in the report?
What types of companies are involved in the genetic disorder deals reported?
